Hypo-Attenuated Leaflet Thickening and Reduced Leaflet Motion in Sutureless Bioprosthetic Aortic Valves

Magnus Dalén, Ulrik Sartipy, Kerstin Cederlund, Anders Franco-Cereceda, Anders Svensson, Raquel Themudo, Peter Svenarud, Elin Bacsovics Brolin, Magnus Dalén, Ulrik Sartipy, Kerstin Cederlund, Anders Franco-Cereceda, Anders Svensson, Raquel Themudo, Peter Svenarud, Elin Bacsovics Brolin

Abstract

Background: The prevalence of hypo-attenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) is unknown in surgically implanted bioprostheses because systematic investigation of HALT and/or RLM is limited to a few catheter-based valves. The aim of this study was to investigate the prevalence of HALT and RLM by cardiac computed tomography in patients who underwent surgical aortic valve replacement and received a Perceval sutureless aortic valve bioprosthesis.

Methods and results: This was a single-center prospective observational study that included 47 patients (83.5% of the total number of implantations) who underwent surgical aortic valve replacement with implantation of the Perceval sutureless bioprosthesis (LivaNova PLC, London, UK) at Karolinska University Hospital in Stockholm, Sweden from 2012 to 2016 and were studied by cardiac computed tomography. Cardiac computed tomography was performed at a median of 491 days (range 36-1247 days) postoperatively. HALT was found in 18 (38%) patients and RLM in 13 (28%) patients. All patients with RLM had HALT. Among patients with HALT, 5 out of 18 patients (28%) were treated with anticoagulation (warfarin or any novel oral anticoagulant) at the time of cardiac computed tomography. Among patients with RLM, 3 out of 13 patients (23%) were treated with anticoagulation.

Conclusions: HALT and RLM were prevalent in the surgically implanted Perceval sutureless aortic valve bioprosthesis. Both HALT and RLM were found in patients with ongoing anticoagulation treatment. Whether these findings are associated with adverse events needs further study.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02671474.

Keywords: aortic valve surgery; bioprosthesis; cardiac computed tomography; leaflet motion; leaflet thickening.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Figures

Figure 1
Figure 1
Study flow chart and prevalence of hypo‐attenuated leaflet thickening and reduced leaflet motion in relation to anticoagulation treatment (warfarin or any novel oral anticoagulant). HALT indicates hypo‐attenuated leaflet thickening.

References

    1. Pache G, Schoechlin S, Blanke P, Dorfs S, Jander N, Arepalli CD, Gick M, Buettner HJ, Leipsic J, Langer M, Neumann FJ, Ruile P. Early hypo‐attenuated leaflet thickening in balloon‐expandable transcatheter aortic heart valves. Eur Heart J. 2016;37:2263–2271.
    1. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, de Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Sondergaard L. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–2024.
    1. Leetmaa T, Hansson NC, Leipsic J, Jensen K, Poulsen SH, Andersen HR, Jensen JM, Webb J, Blanke P, Tang M, Norgaard BL. Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast‐enhanced multidetector computed tomography. Circ Cardiovasc Interv. 2015;8:e001596. DOI: .
    1. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, Jilaihawi H, Shiota T, Abramowitz Y, Jorgensen TH, Rami T, Israr S, Fontana G, de Knegt M, Fuchs A, Lyden P, Trento A, Bhatt DL, Leon MB, Makkar RR; Resolve, Investigators S . Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017; pii: S0140‐6736(17)30757‐2. DOI: . [Epub ahead of print].
    1. Laschinger JC, Wu C, Ibrahim NG, Shuren JE. Reduced leaflet motion in bioprosthetic aortic valves—the FDA perspective. N Engl J Med. 2015;373:1996–1998.
    1. Anselmino M, Andria A. Embolization from biological prosthetic aortic root. Eur J Echocardiogr. 2006;7:228–229.
    1. Pozsonyi Z, Lengyel M. Successful thrombolysis of late, non‐obstructive mitral bioprosthetic valve thrombosis: case report and review of the literature. J Heart Valve Dis. 2011;20:526–530.
    1. Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007;93:137–142.
    1. LivaNova PLC announces the first patient enrolled in the PERSIST‐AVR Trial. Available at: . Accessed May 21, 2016.
    1. Fischlein T, Meuris B, Hakim‐Meibodi K, Misfeld M, Carrel T, Zembala M, Gaggianesi S, Madonna F, Laborde F, Asch F, Haverich A; Investigators CT . The sutureless aortic valve at 1 year: a large multicenter cohort study. J Thorac Cardiovasc Surg. 2016;151:1617–1626.e4.
    1. Budoff MJ, Cohen MC, Garcia MJ, Hodgson JM, Hundley WG, Lima JA, Manning WJ, Pohost GM, Raggi PM, Rodgers GP, Rumberger JA, Taylor AJ, Creager MA, Hirshfeld JW Jr, Lorell BH, Merli G, Rodgers GP, Tracy CM, Weitz HH; American College of Cardiology F, American Heart A, American College of Physicians Task Force on Clinical C, American Society of E, American Society of Nuclear C, Society of Atherosclerosis I, Society for Cardiovascular A, Interventions, Society of Cardiovascular Computed T . ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. Circulation. 2005;112:598–617.
    1. Pflederer T, Achenbach S. Aortic valve stenosis: CT contributions to diagnosis and therapy. J Cardiovasc Comput Tomogr. 2010;4:355–364.
    1. Hansson NC, Grove EL, Andersen HR, Leipsic J, Mathiassen ON, Jensen JM, Jensen KT, Blanke P, Leetmaa T, Tang M, Krusell LR, Klaaborg KE, Christiansen EH, Terp K, Terkelsen CJ, Poulsen SH, Webb J, Botker HE, Norgaard BL. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68:2059–2069.
    1. Yanagisawa R, Hayashida K, Yamada Y, Tanaka M, Yashima F, Inohara T, Arai T, Kawakami T, Maekawa Y, Tsuruta H, Itabashi Y, Murata M, Sano M, Okamoto K, Yoshitake A, Shimizu H, Jinzaki M, Fukuda K. Incidence, predictors, and mid‐term outcomes of possible leaflet thrombosis after TAVR. JACC Cardiovasc Imaging. 2016; pii: S1936‐878X(16)30897‐X. DOI: . [Epub ahead of print].
    1. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126:1938–1945.
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD; American College of Cardiology/American Heart Association Task Force on Practice G . 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–e185.
    1. Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio‐Thoracic S , Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron‐Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–2496.
    1. Perceval sutureless aortic heart valve instructions for use. Available at: . Accessed June 7, 2016.
    1. Huck V, Schneider MF, Gorzelanny C, Schneider SW. The various states of von Willebrand factor and their function in physiology and pathophysiology. Thromb Haemost. 2014;111:598–609.
    1. Meuris B, Flameng WJ, Laborde F, Folliguet TA, Haverich A, Shrestha M. Five‐year results of the pilot trial of a sutureless valve. J Thorac Cardiovasc Surg. 2015;150:84–88.
    1. Shrestha M, Fischlein T, Meuris B, Flameng W, Carrel T, Madonna F, Misfeld M , Folliguet T, Haverich A, Laborde F. European multicentre experience with the sutureless Perceval valve: clinical and haemodynamic outcomes up to 5 years in over 700 patients. Eur J Cardiothorac Surg. 2016;49:234–241.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅